Avalglucosidase alfa improves motor and respiratory function in late-onset Pompe disease: A COMET win-ratio analysis

被引：0
|
作者：
Diaz-Manera, Jordi [1 ]
Dimachkie, Mazen M. [2 ]
Ishak, Jack [3 ]
Caro, Jaime [4 ]
Hamed, Alaa [5 ]
Franca, Lionel Riou [6 ]
Thibault, Nathan [5 ]
Shukla, Pragya [3 ]
Berger, Kenneth I. [7 ]
Boentert, Matthias [8 ]
机构：
[1] Newcastle Univ, John Walton Muscular Dystrophy Res Ctr, Ctr Life, Newcastle Upon Tyne, England
[2] Univ Kansas, Dept Neurol, Med Ctr, Kansas City, KS USA
[3] Evidera, Montreal, PQ, Canada
[4] Evidera, Waltham, MA USA
[5] Sanofi, Cambridge, MA USA
[6] Sanofi, Paris, France
[7] New York Univ, Div Pulm Crit Care & Sleep Med, Grossman Sch Med, New York, NY USA
[8] Munster Univ Hosp, Dept Neurol, Munster, Germany
来源：
MOLECULAR GENETICS AND METABOLISM | 2023年 / 138卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2022.107076
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
93
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [41] Analysis of pooled data from clinical trials in treatment-naive patients with late-onset Pompe disease (LOPD) to inform on the efficacy of avalglucosidase alfa
    Mozaffar, Tahseen
    Franca, Lionel Riou
    Msihid, Jerome
    Shukla, Pragya
    Proskorovsky, Irina
    Zhou, Tianyue
    Fournier, Marie
    Periquet, Magali
    Haack, Kristina An
    Pollissard, Laurence
    Straub, Volker
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S86 - S86
  • [42] Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks A Phase 3 Randomized Clinical Trial
    Kishnani, Priya S.
    Diaz-Manera, Jordi
    Toscano, Antonio
    Clemens, Paula R.
    Ladha, Shafeeq
    Berger, Kenneth I.
    Kushlaf, Hani
    Straub, Volker
    Carvalho, Gerson
    Mozaffar, Tahseen
    Roberts, Mark
    Attarian, Shahram
    Chien, Yin-Hsiu
    Choi, Young-Chul
    Day, John W.
    Erdem-Ozdamar, Sevim
    Illarioshkin, Sergey
    Goker-Alpan, Ozlem
    Kostera-Pruszczyk, Anna
    van der Ploeg, Ans T.
    An Haack, Kristina
    Huynh-Ba, Olivier
    Tammireddy, Swathi
    Thibault, Nathan
    Zhou, Tianyue
    Dimachkie, Mazen M.
    Schoser, Benedikt
    JAMA NEUROLOGY, 2023, 80 (06) : 558 - 567
  • [43] LATE-ONSET POMPE DISEASE (LOPD) PATIENTS TREATED WITH AVALGLUCOSIDASE ALFA SHOW FAVORABLE RESULTS COMPARED TO CIPAGLUCOSIDASE ALFA PLUS MIGLUSTAT: INDIRECT TREATMENT COMPARISON
    Roberts, M.
    Proskorovsky, I
    Guyot, P.
    Shukla, P.
    Periquet, M.
    Thibault, N.
    Hamed, A.
    Franca, Riou L.
    Pollissard, L.
    VALUE IN HEALTH, 2023, 26 (06) : S37 - S38
  • [44] Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease
    Tiraboschi, Gilles
    Marchionni, David
    Tuffal, Gilles
    Fabre, David
    Martinez, Jean-Marie
    Haack, Kristina An
    Miossec, Patrick
    Kittner, Barbara
    Daba, Nadia
    Hurbin, Fabrice
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2023, 50 (06) : 461 - 474
  • [45] Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease
    Gilles Tiraboschi
    David Marchionni
    Gilles Tuffal
    David Fabre
    Jean-Marie Martinez
    Kristina An Haack
    Patrick Miossec
    Barbara Kittner
    Nadia Daba
    Fabrice Hurbin
    Journal of Pharmacokinetics and Pharmacodynamics, 2023, 50 : 461 - 474
  • [46] Mini-COMET: effects of avalglucosidase alfa on ptosis in participants with infantile-onset Pompe disease previously treated with alglucosidase alfa
    Prakalapakorn, S. Grace
    Davison, James
    Broomfield, Alexander
    Kronn, David
    Labarthe, Francois
    Brassier, Anais
    Hahn, Si Houn
    Kumada, Satoko
    Ohki, Hirotaka
    Pichard, Samia
    Haack, Kristina An
    Johnson, Judith
    Meng, Xianzhang
    Chien, Yin-Hsiu
    Kishnani, Priya
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 : S137 - S137
  • [47] Motor Function Characteristics of Adults With Late-Onset Pompe Disease A Systematic Scoping Review
    Maulet, Theo
    Bonnyaud, Celine
    Weill, Catherine
    Laforet, Pascal
    Cattagni, Thomas
    NEUROLOGY, 2023, 100 (01) : E72 - E83
  • [48] WIN RATIO ANALYSES OF MULTIPLE ENDPOINTS IN RARE DISEASE TRIALS: A CASE-STUDY BASED ON A TRIAL OF AVAGLUCOSIDASE ALFA IN LATE-ONSET POMPE DISEASE (LOPD)
    Ishak, K. J.
    Caro, J. J.
    Hamed, A.
    Riou-Franca, L.
    Thibault, N.
    Shukla, P.
    Berger, K., I
    Diaz-Manera, J.
    Dimachkie, M. M.
    Boentert, M.
    VALUE IN HEALTH, 2022, 25 (12) : S487 - S488
  • [49] A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
    Byrne, Barry J.
    Geberhiwot, Tarekegn
    Barshop, Bruce A.
    Barohn, Richard
    Hughes, Derralynn
    Bratkovic, Drago
    Desnuelle, Claude
    Laforet, Pascal
    Mengel, Eugen
    Roberts, Mark
    Haroldsen, Peter
    Reilley, Kristin
    Jayaram, Kala
    Yang, Ke
    Walsh, Liron
    ORPHANET JOURNAL OF RARE DISEASES, 2017, 12
  • [50] A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
    Barry J. Byrne
    Tarekegn Geberhiwot
    Bruce A. Barshop
    Richard Barohn
    Derralynn Hughes
    Drago Bratkovic
    Claude Desnuelle
    Pascal Laforet
    Eugen Mengel
    Mark Roberts
    Peter Haroldsen
    Kristin Reilley
    Kala Jayaram
    Ke Yang
    Liron Walsh
    Orphanet Journal of Rare Diseases, 12
12345